Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing incidence in recent years due to the aging population. Genetic mutations alone only explain <10% of PD cases, while environmental factors, including small molecules, may play a significant role in PD. In the present work, 22 plasma (11 PD, 11 control) and 19 feces samples (10 PD, 9 control) were analyzed by non-target high-resolution mass spectrometry (NT-HRMS) coupled to two liquid chromatography (LC) methods (reversed-phase (RP) and hydrophilic interaction liquid chromatography (HILIC)). A cheminformatics workflow was optimized using open software (MS-DIAL and patRoon) and open databases (all public MSP-formatted spectral libraries for MS-D...
Abstract Background Untargeted high-resolution metabolomic profiling provides simultaneous measureme...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be fou...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow...
The plasma of Parkinson's disease (PD) patients may contain various altered metabolites associated ...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
Parkinson’s disease is the second most common neurodegenerative disease. In the vast majority of cas...
Abstract Background Untargeted high-resolution metabolomic profiling provides simultaneous measureme...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be fou...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow...
The plasma of Parkinson's disease (PD) patients may contain various altered metabolites associated ...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
Parkinson’s disease is the second most common neurodegenerative disease. In the vast majority of cas...
Abstract Background Untargeted high-resolution metabolomic profiling provides simultaneous measureme...
Abstract Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challen...
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be fou...